About WhiteLab Genomics

WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.

<problem> Genomic medicine development is often slow and costly due to the complexities of payload and vector design, which require extensive datasets and in-silico simulations. Optimizing these designs and assessing genotoxicity can be challenging, hindering the efficient development of gene and cell therapies. </problem> <solution> WhiteLab Genomics offers an AI-driven platform that accelerates the discovery and development of genomic medicines. The platform leverages graph knowledge technology and machine learning to optimize payload and vector design for gene, RNA, and cell therapies. By providing in-silico simulations based on exhaustive datasets, the platform enables scientists to answer key scientific and technological questions, such as optimizing payload and vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. This approach reduces the development time and costs associated with bringing genomic medicines to market. </solution> <features> - AI-powered platform for optimizing payload and vector design - Graph knowledge technology and machine learning algorithms - In-silico simulations based on exhaustive datasets - Genotoxicity assessment capabilities - Identification of optimal experimental protocols for in vivo and in vitro strategies - Support for gene therapy, RNA therapy, and cell therapy development </features> <target_audience> The primary audience includes scientists and researchers in the field of genomic medicine, particularly those focused on gene therapy, RNA therapy, and cell therapy. </target_audience>

What does WhiteLab Genomics do?

Where is WhiteLab Genomics located?

WhiteLab Genomics is based in Paris, France.

When was WhiteLab Genomics founded?

WhiteLab Genomics was founded in 2019.

How much funding has WhiteLab Genomics raised?

WhiteLab Genomics has raised 10500000.

Location

Paris, France

Founded

2019

Funding

10500000

Employees

50 employees

Major Investors

Y Combinator, Debiopharm Group, Omnes Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

WhiteLab Genomics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

whitelabgx.com 5K+

Crunchbase

Founded 2019 – Paris, France

Funding

Estimated Funding

$10M+

Major Investors

Y Combinator, Debiopharm Group, Omnes Capital

Team (50+)

No team information available.

Company Description

Problem

Genomic medicine development is often slow and costly due to the complexities of payload and vector design, which require extensive datasets and in-silico simulations. Optimizing these designs and assessing genotoxicity can be challenging, hindering the efficient development of gene and cell therapies.

Solution

WhiteLab Genomics offers an AI-driven platform that accelerates the discovery and development of genomic medicines. The platform leverages graph knowledge technology and machine learning to optimize payload and vector design for gene, RNA, and cell therapies. By providing in-silico simulations based on exhaustive datasets, the platform enables scientists to answer key scientific and technological questions, such as optimizing payload and vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. This approach reduces the development time and costs associated with bringing genomic medicines to market.

Features

AI-powered platform for optimizing payload and vector design

Graph knowledge technology and machine learning algorithms

In-silico simulations based on exhaustive datasets

Genotoxicity assessment capabilities

Identification of optimal experimental protocols for in vivo and in vitro strategies

Support for gene therapy, RNA therapy, and cell therapy development

Target Audience

The primary audience includes scientists and researchers in the field of genomic medicine, particularly those focused on gene therapy, RNA therapy, and cell therapy.